Abattis Bioceuticals (ATTBF) Stock Price, News & Analysis

Company Overview

Abattis Bioceuticals Corp. is a Canadian life sciences company focused on the research, development and manufacture of botanical-based health products and contract research services. Through its Innovation Centre in Toronto, the company conducts pre-clinical testing, analytical method development and formulation work using proprietary extraction and purification techniques. Its Ancaster facility serves as a licensed processing centre that produces botanical extracts, distillates and isolates for pharmaceutical, nutraceutical and wellness applications under both in-house brands and white-label contracts.

In 2021, Abattis expanded its service offering with the acquisition of Conifer Pharmaceuticals, a contract research organization specializing in high-throughput screening, genome engineering and drug candidate evaluation. This addition bolstered Abattis’s capacity to support external clients in the identification and optimization of novel therapeutic compounds, while also advancing its own pipeline of botanical derivatives targeting inflammation, metabolic disorders and other health indications.

Geographically, Abattis operates primarily within Canada but has established partnerships and distribution channels in the United States and select European markets. Its product portfolio spans standardized botanical extracts, specialty oils and custom formulations designed to meet regulatory and quality standards across multiple jurisdictions. Through collaborative research agreements with academic institutions and industry partners, the company continues to explore opportunities in emerging markets and novel delivery systems.

Abattis is led by a management team with deep experience in pharmaceutical development, regulatory affairs and commercial operations. Guided by CEO Michael Frank and supported by a board of directors with backgrounds in life sciences investment and biotechnology, the company aims to leverage its integrated R&D and manufacturing platform to drive growth in the botanical and health sciences sectors.

Key Stats

• Today's Range: $0.0001 to $0.0001
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0001
• Volume: 3,300 shs
• Average Volume: 11,650 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ATTBF Stock Analysis - Frequently Asked Questions

How have ATTBF shares performed this year?

Abattis Bioceuticals' stock was trading at $0.0001 on January 1st, 2025. Since then, ATTBF stock has increased by 0.0% and is now trading at $0.0001.

How do I buy shares of Abattis Bioceuticals?

Shares of ATTBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:ATTBF
• CIK: N/A
• Web: www.abattis.com
• Phone: 808-650-3007
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A